Journal News

Matrix metalloproteinase inhibitor reduces cancer invasion

Emily Ulrich
Oct. 8, 2025

Matrix metalloproteinase-9, or MMP-9, remodels the extracellular matrix, but its dysregulation contributes to many diseases, including metastatic cancer. Efforts to develop MMP-9 inhibitors to treat cancer have been hampered by small molecules’ poor specificity and side effects from blocking other MMPs with similar catalytic domains. Tissue inhibitors of metalloproteinases, or TIMPs, block multiple MMPs, but tweaking their specificity is possible since some MMPs have unique domains that interact with larger protein inhibitors. Alireza Shoari at the Mayo Clinic and a team in the U.S. aimed to target the MMP-9 fibronectin domain for TIMP binding. They published their recent study in the Journal of Biological Chemistry.

Using yeast surface display, the team screened a large library in a directed evolution experiment to identify a TIMP-1 variant with enhanced binding to the MMP-9 catalytic and fibronectin domains. They selected the strongest binder, TIMP-1-C15, and confirmed its MMP-9 inhibition in enzyme assays. The authors demonstrated that TIMP-1-C15 inhibition decreases if the fibronectin domain is removed, providing evidence that the fibronectin domain heavily contributes to the interaction.

Flow cytometry and dose-dependent inhibition assays showed that TIMP-1-C15 selectively binds and inhibits MMP-9 over MMP-1, -2 and -3, even though MMP-2 contains a similar fibronectin domain. In cell invasion assays with triple-negative breast cancer cells that require MMP-9, TIMP-1-C15 reduced cell invasion at least as well, or slightly better, compared to unmodified TIMP-1.

Future structural studies will reveal how TIMP-1-C15 binds MMP-9’s fibronectin domain over MMP-2’s similar domain. In addition, animal model testing will help determine TIMP-1-C15’s potential to treat metastatic cancer.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Mapping the placenta’s hormone network
Journal News

Mapping the placenta’s hormone network

Oct. 21, 2025

Study uncovers how the placenta actively metabolizes not only glucocorticoids but also novel androgens and progesterones, reshaping our understanding of pregnancy and its complications.

Biochemists and molecular biologists sweep major 2025 honors
News

Biochemists and molecular biologists sweep major 2025 honors

Oct. 20, 2025

Recent Nobel, MacArthur and Kimberly Prize honorees highlight the power of biochemistry and molecular biology to drive discovery, including immune tolerance, vaccine design and metabolic disease, and to advance medicine and improve human health.

Spider-like proteins spin defenses to control immunity
News

Spider-like proteins spin defenses to control immunity

Oct. 17, 2025

Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.

A biological camera: How AI is transforming retinal imaging
Feature

A biological camera: How AI is transforming retinal imaging

Oct. 15, 2025

AI is helping clinicians see a more detailed view into the eye, allowing them to detect diabetic retinopathy earlier and expand access through tele-ophthalmology. These advances could help millions see a clearer future.

AI in the lab: The power of smarter questions
Essay

AI in the lab: The power of smarter questions

Oct. 14, 2025

An assistant professor discusses AI's evolution from a buzzword to a trusted research partner. It helps streamline reviews, troubleshoot code, save time and spark ideas, but its success relies on combining AI with expertise and critical thinking.

Training AI to uncover novel antimicrobials
Feature

Training AI to uncover novel antimicrobials

Oct. 9, 2025

Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.